GEN Exclusives

More »

The Lists

More »
Sep 9, 2013

Top 20 CEO Salaries: Biotech Tool Providers

Running a large instrumentation company is not a bad-paying job as these 20 men can attest.

Top 20 CEO Salaries: Biotech Tool Providers

Less than half of the CEOs on this list saw their total compensation increase over the previous year. Find out which ones did below. [© ALYUSHIN - Fotolia.com]

  • Following is a list of 20 current or former CEOs of life sciences tools and technologies providers who led their companies for at least part of 2012, ranked by their "total compensation" last year. Total compensation goes beyond salary to include bonuses, stock awards, stock option awards, nonequity incentive plan compensation, and all other sources of compensation. For each CEO ranked, the list offers 2012 and 2011 compensation, the percentage change between the amounts.

    This year, unlike last year, rankings are of individuals rather than companies to align with GEN’s similarly reranked list of biopharma CEOs published earlier this year. Also unlike GEN’s first such list in 2012 (See "Top 15 CEO Salaries: Biotech Tool Providers", published September 11, 2012, in GEN), less than half (eight of 20 CEOs) saw their total compensation increase over the previous year, compared with 10 of the top 15 CEOs ranked by GEN in 2011.

    One possible reason: Most tools companies focused more of their spending on R&D (See "Top 22 R&D Spenders among Tool and Technologies Companies," published in GEN April 2, 2013). Another possibility: Tools and tech companies opted to use cash on hand for acquisitions as the segment consolidates among fewer players, reflected best by Thermo Fisher Scientific’s plans announced in April to acquire Life Technologies.

    Four of this year’s Top 20 CEOs either assumed their positions or added to their responsibilities in 2011 or 2012. As with the biopharma CEO pay list, all of the top-paid tools-tech CEOs were male.

  • #10. Olivier A. Filliol

    President and CEO of Mettler Toledo

    2012 Compensation: $4,384,508

    2011 Compensation: $5,251,183

    % Change: -16.5%

  • #9. Norman Schwartz

    President, CEO, and Chairman5 of Bio-Rad Laboratories

    2012 Compensation: $4,520,753

    2011 Compensation: $3,844,998

    % Change: 17.6%

  • #8. Rakesh Sachdev

    President and CEO of Sigma-Aldrich

    2012 Compensation: $4,585,422

    2011 Compensation: $3,915,529

    % Change: 17.1%

  • #7. Jay T. Flatley

    President, CEO, and Director of Illumina

    2012 Compensation: $8,171,0806

    2011 Compensation: $9,944,147

    % Change: -17.8%

  • #6. Vincent A. Forlenza

    Chairman, CEO, and President of Becton Dickinson

    Year Ending September 30, 2012 Compensation: $9,418,2767

    Year Ending September 30, 2011 Compensation: $5,018,8547,8

    % Change: 87.7%

  • #5. William P. Sullivan

    President and CEO of Agilent Technologies

    2012 Compensation: $10,135,717

    2011 Compensation: $10,252,264

    % Change: -1.1%

  • #4. Gregory T. Lucier

    Chairman and CEO of Life Technologies9

    2012 Compensation: $10,268,445

    2011 Compensation: $10,897,630

    % Change: -5.8%

  • #3. Robert F. Friel

    Chairman and CEO of PerkinElmer

    2012 Compensation: $10,832,610

    2011 Compensation: $12,819,181

    % Change: -15.5%

  • #2. Marc N. Casper

    President and CEO of Thermo Fisher Scientific

    2012 Compensation: $13,555,10110

    2011 Compensation: $5,516,567

    % Change: 145.7%

  • #1. H. Lawrence Culp, Jr.

    President and CEO of Danaher

    2012 Compensation: $21,898,728

    2011 Compensation: $21,652,417

    % Change: 1.1%



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Stopping Research Fraud

What is the best approach to curbing scientific misconduct and outright fraud?